Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

Zhuan'e Yao; Pengbo Wang; Qinjuan Fu; Qiong Song; Ai Liu; Huan Li; Wei Wang; Peng Zhang

doi:10.12659/MSM.943529

12 July 2024 : Clinical Research

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

Zhuan'e Yao^{ABCDEFG 1,2}, Pengbo Wang^{ABCDE 1}, Qinjuan Fu^{BD 1}, Qiong Song^{BC 1}, Ai Liu^{DF 1}, Huan Li^{BCD 1}, Wei Wang^{DF 1}, Peng Zhang^{ACDEF 2*}

DOI: 10.12659/MSM.943529

Med Sci Monit 2024; 30:e943529

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 (A) Change in New York Heart Association (NYHA) Class after treatment with sacubitril/valsartan. (B) Change in left ventricular ejection fraction (LVEF) after treatment with sacubitril/valsartan. (C) Change in cardiac function after treatment with sacubitril/valsartan. (D) Change in quality of life after treatment with sacubitril/valsartan.

Back to the Article

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

Your Privacy